Sign in →

Test Code APOA1 Apolipoprotein A1, Serum


Specimen Required


Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL

Collection Instructions:

1. Centrifuge and aliquot within 2 hours of collection.

2. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.


Useful For

Evaluating risk for atherosclerotic cardiovascular disease

 

Aiding in the detection of Tangier disease

Method Name

Automated Turbidimetric Immunoassay

Reporting Name

Apolipoprotein A1, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 8 days
  Frozen  60 days
  Ambient  24 hours

Reference Values

Males

Age

Apolipoprotein A (mg/dL)

<24 months

Not established

2-17 years

Low: <115

Borderline low: 115-120

Acceptable: >120

>18 years

≥120

 

Females

Age

Apolipoprotein A (mg/dL)

<24 months

Not established

2-17 years

Low: <115

Borderline low: 115-120

Acceptable: >120

>18 years

≥140

Interpretation

Low levels of apolipoprotein A1 (ApoA1) confer increased risk of atherosclerotic cardiovascular disease.

 

ApoA1 below 25 mg/dL may aid in the detection of a genetic disorder such as Tangier disease.

 

ApoA1 is often interpreted as a ratio with apolipoprotein B (ApoB).

Clinical Reference

1. Sorci-Thomas MG, Thomas MJ: Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not. J Cardiovasc. Pharmacol 2013;62:239-246

2. Di Angelantonio E, Sarwar N, Perry P, et al: Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000

3. McQueen MJ, Hawken S, Wang X, et al: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet 2008;372:224-233

4. Sung KC, Wild SH, Byrne CD: Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. Atherosclerosis 2013;231:181-186

5. Boekholdt SM, Arsenault BJ, Hovingh GK, et.al: Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis. Circulation 2013;128:1504-1512

Day(s) Performed

Monday through Sunday

Report Available

1 to 2 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

82172

LOINC Code Information

Test ID Test Order Name Order LOINC Value
APOA1 Apolipoprotein A1, S 1869-7

 

Result ID Test Result Name Result LOINC Value
APOA1 Apolipoprotein A1, S 1869-7